全文获取类型
收费全文 | 91801篇 |
免费 | 45249篇 |
国内免费 | 207篇 |
专业分类
耳鼻咽喉 | 1735篇 |
儿科学 | 4902篇 |
妇产科学 | 1207篇 |
基础医学 | 17809篇 |
口腔科学 | 5272篇 |
临床医学 | 13651篇 |
内科学 | 26187篇 |
皮肤病学 | 7744篇 |
神经病学 | 14553篇 |
特种医学 | 2741篇 |
外国民族医学 | 1篇 |
外科学 | 16161篇 |
综合类 | 473篇 |
一般理论 | 45篇 |
预防医学 | 6926篇 |
眼科学 | 1777篇 |
药学 | 6568篇 |
2篇 | |
中国医学 | 1141篇 |
肿瘤学 | 8362篇 |
出版年
2023年 | 185篇 |
2022年 | 113篇 |
2021年 | 1826篇 |
2020年 | 5277篇 |
2019年 | 11227篇 |
2018年 | 10607篇 |
2017年 | 11781篇 |
2016年 | 12446篇 |
2015年 | 12368篇 |
2014年 | 12440篇 |
2013年 | 13203篇 |
2012年 | 5487篇 |
2011年 | 5461篇 |
2010年 | 9729篇 |
2009年 | 5905篇 |
2008年 | 3119篇 |
2007年 | 2106篇 |
2006年 | 2082篇 |
2005年 | 1701篇 |
2004年 | 1659篇 |
2003年 | 1614篇 |
2002年 | 1554篇 |
2001年 | 1116篇 |
2000年 | 985篇 |
1999年 | 512篇 |
1998年 | 156篇 |
1997年 | 133篇 |
1996年 | 116篇 |
1995年 | 114篇 |
1994年 | 108篇 |
1993年 | 82篇 |
1992年 | 181篇 |
1991年 | 164篇 |
1990年 | 174篇 |
1989年 | 186篇 |
1988年 | 156篇 |
1987年 | 159篇 |
1986年 | 133篇 |
1985年 | 113篇 |
1984年 | 95篇 |
1983年 | 83篇 |
1982年 | 40篇 |
1981年 | 51篇 |
1980年 | 40篇 |
1979年 | 52篇 |
1978年 | 37篇 |
1977年 | 31篇 |
1975年 | 34篇 |
1974年 | 27篇 |
1973年 | 29篇 |
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
11.
Jakub Pazdrowski Aleksandra Daczak‐Pazdrowska Adriana Polaska Joanna Ka
mierska Wojciech Barczak Mateusz Szewczyk Pawe Golusiski Zygmunt Adamski Ryszard aba Wojciech Golusiski 《Skin research and technology》2019,25(6):857-861
Radiodermatitis is one of the commonest side effects of radiotherapy. They are usually assessed by semi‐quantitative clinical scores, which are not validated and may be subject to inter‐observer variability. A few previous studies suggested that high‐frequency ultrasonography (HF‐USG) is useful in the assessment of the acute phase of radiation dermatitis in breast cancer patients. (a) To monitor skin changes by HF‐USG during the course of radiotherapy due to head and neck cancers, and (b) to determine whether there is any connection between skin sonograms and the skin scoring criteria. This prospective, observational study includes patients diagnosed with head and neck cancers, treated with radiotherapy or concomitant chemoradiation. The final analysis includes six patients. In every patient, the HF‐USG as well as dermatological assessment (target lesion score—TLS and CACE v. 4.0) were performed 4×: before, in the middle, day after, and 3 months after radiotherapy. There were significant differences between non‐irradiated skin thickness and thickness of skin with clinically obvious radiodermatitis (TLS grade 1‐4; P < .0001), as well as between irradiated, unchanged skin thickness (TLS grade 0) and thickness of skin with clinically obvious radiodermatitis (TLS grade 1‐4; P = .0002). There was no significant difference between non‐irradiated and irradiated, unchanged skin thickness (TLS grade 0; P = .9318). In four patients, we demonstrated subepidermal low echogenic band (SLEB). HF‐USG can be useful tool to noninvasive and objective assessment of skin changes during radiotherapy. 相似文献
12.
Jean‐Franois Etter 《Addiction (Abingdon, England)》2019,114(12):2252-2256
13.
Liam Masterson James Howard Jazmina Gonzalez-Cruz Christopher Jackson Catherine Barnett Lewis Overton Howard Liu Rahul Ladwa Fiona Simpson Margie McGrath Ben Wallwork Terry Jones Christian Ottensmeier Melvin L.K. Chua Chris Perry Rajiv Khanna Benedict Panizza Sandro Porceddu Matt Lechner 《International journal of cancer. Journal international du cancer》2020,146(8):2305-2314
Now is an exciting era of development in immunotherapy checkpoint inhibitors and their effect on the treatment of NPC. While the general prognosis of R/M disease is poor, immunotherapy offers some promise in a malignancy associated with EBV and characterized by a peritumoural immune infiltrate. Our study aims to review past and on-going clinical trials of monoclonal antibody therapies against the checkpoint inhibitors (e.g. PD1 and CTLA-4), in R/M NPC. All randomized and nonrandomized controlled trials involving immune checkpoint inhibitor interventions for treatment of NPC were included in the study. We utilized a validated “risk of bias” tool to assess study quality. Four separate Phase I–II trials report the potential of PD1 inhibitor treatment for patients with NPC. Within the observed groups, camrelizumab combined with chemotherapy achieved an objective response in 91% of patients as first-line treatment for metastatic NPC (PFS 68% at 1-year) but this was associated with a high rate of grade >3 adverse events (87%; CTCAE version 4.03). The remaining three studies focused on recurrent NPC disease in patients who had received at least one line of prior chemotherapy. Within this group, camrelizumab monotherapy achieved an objective response in 34% of patients (PFS 27% at 1-year; range across all three studies 20.5–34%). No NPC trial has yet reported on specific outcomes for non-PD1 checkpoint inhibitors but 11 on-going studies include alternative targets (e.g. PD-L1/CTLA-4) as combination or monotherapy treatments. In considering checkpoint immunotherapies for NPC, initial results show promise for anti-PD1 interventions. Further phase I–III trials are in progress to clarify clinical outcomes, fully determine safety profiles, and optimize drug combinations and administration schedules. 相似文献
14.
15.
16.
17.
18.
Anne E. Kazak Fang Fang Chen Wei‐Ting Hwang Martha A. Askins Gabriela Vega E. Anders Kolb Anne Reilly Lamia P. Barakat 《Pediatric blood & cancer》2020,67(2)
Purpose: Family psychosocial risk in pediatric oncology can be assessed using the Psychosocial Assessment Tool (PAT), a brief parent report screener based on the Pediatric Psychosocial Preventative Health Model (PPPHM; universal, targeted, and clinical). However, little is known about risk over the course of treatment and its association with medical and psychosocial healthcare utilization. Methods: Primary caregivers of children with cancer participated in this prospective multisite investigation, completing the PAT at diagnosis (T1; n = 396) and 6 months later (T2; n = 304). Healthcare utilization data were extracted from electronic health records. Results: The distribution of PPPHM risk levels at T1 and T2 was highly consistent for the samples. Two‐thirds of families remained at the same level of risk, 18% decreased and 16% increased risk level. Risk was not related to sociodemographic or treatment variables. The PAT risk score correlated with psychosocial contacts over the 6‐month period. Conclusions: Although the majority of families reported universal (low) risk on the PAT and were stable in their risk level over 6 months, reassessing risk is helpful in identifying those families who report higher level of risk during treatment than at diagnosis. PAT scores were related to psychosocial services that are provided to most but not all families and could be tailored more specifically to match risk and delivery of evidence‐based care. 相似文献
19.
Ángel Becerra Héctor Trujillo Lucía Valencia Aurelio Rodríguez‐Pérez 《Brazilian Journal of Anesthesiology》2019,69(2):200-203